TY - JOUR
T1 - Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure
T2 - Results from the BACH multinational study
AU - Daniels, Lori B.
AU - Clopton, Paul
AU - Potocki, Mihael
AU - Mueller, Christian
AU - McCord, James
AU - Richards, Mark
AU - Hartmann, Oliver
AU - Anand, Inder S.
AU - Wu, Alan H B
AU - Nowak, Richard
AU - Peacock, W. Frank
AU - Ponikowski, Piotr
AU - Mockel, Martin
AU - Hogan, Christopher
AU - Filippatos, Gerasimos S.
AU - Di Somma, Salvatore
AU - Ng, Leong
AU - Neath, Sean Xavier
AU - Christenson, Robert
AU - Morgenthaler, Nils G.
AU - Anker, Stefan D.
AU - Maisel, Alan S.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Aims Midregional pro atrial natriuretic peptide (MR-proANP) is useful for diagnosing acute heart failure (HF) in patients presenting to the Emergency Department with dyspnoea. Optimal interpretation of MR-proANP requires understanding of how various demographic variables influence its levels and performance as a diagnostic marker. We sought to determine how age, race, sex, and body mass index (BMI) affect the levels and interpretation of MR-proANP for the diagnosis of acute HF. Methods and results The Biomarkers in Acute Heart Failure (BACH) study was an international 15-centre study of 1641 patients presenting to the Emergency Department with acute dyspnoea. Of these, 1352 had complete information on age, race, sex, and BMI. MR-proANP levels increased with age and were higher in men and in patients with lower BMI. MR-proANP performed better as a diagnostic marker in younger individuals and in blacks compared with whites. Despite this, MR-proANP at the recommended cut-off point of 120 pmol/L was >90 sensitive in ruling out the diagnosis of acute HF in all subgroups of patients except white subjects <50 years old. Conclusion Age, race, sex, and BMI affect MR-proANP levels to various degrees. However, the diagnostic performance of the recommended cut-off point of 120 pmol/L to rule out acute HF was robust across most subgroups. Although both sex and BMI affected MR-proANP levels, they did not alter its overall diagnostic performance. Lower cut-off points for MR-proANP could be considered in younger patients and in patients with a higher BMI, to optimize diagnostic sensitivity.
AB - Aims Midregional pro atrial natriuretic peptide (MR-proANP) is useful for diagnosing acute heart failure (HF) in patients presenting to the Emergency Department with dyspnoea. Optimal interpretation of MR-proANP requires understanding of how various demographic variables influence its levels and performance as a diagnostic marker. We sought to determine how age, race, sex, and body mass index (BMI) affect the levels and interpretation of MR-proANP for the diagnosis of acute HF. Methods and results The Biomarkers in Acute Heart Failure (BACH) study was an international 15-centre study of 1641 patients presenting to the Emergency Department with acute dyspnoea. Of these, 1352 had complete information on age, race, sex, and BMI. MR-proANP levels increased with age and were higher in men and in patients with lower BMI. MR-proANP performed better as a diagnostic marker in younger individuals and in blacks compared with whites. Despite this, MR-proANP at the recommended cut-off point of 120 pmol/L was >90 sensitive in ruling out the diagnosis of acute HF in all subgroups of patients except white subjects <50 years old. Conclusion Age, race, sex, and BMI affect MR-proANP levels to various degrees. However, the diagnostic performance of the recommended cut-off point of 120 pmol/L to rule out acute HF was robust across most subgroups. Although both sex and BMI affected MR-proANP levels, they did not alter its overall diagnostic performance. Lower cut-off points for MR-proANP could be considered in younger patients and in patients with a higher BMI, to optimize diagnostic sensitivity.
KW - Age
KW - Gender
KW - Heart failure
KW - Midregional pro atrial natriuretic peptide
KW - Obesity
KW - Race
UR - http://www.scopus.com/inward/record.url?scp=84555204699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84555204699&partnerID=8YFLogxK
U2 - 10.1093/eurjhf/hfr157
DO - 10.1093/eurjhf/hfr157
M3 - Article
C2 - 22140234
AN - SCOPUS:84555204699
SN - 1388-9842
VL - 14
SP - 22
EP - 31
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 1
ER -